pre-IPO PHARMA

navrogen PRESS RELEASE ARCHIVE

May 18, 2023

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers


Apr 12, 2023

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Annual Meeting


Nov 7, 2022

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate


Mar 28, 2022

Navrogen Presents Preclinical Data on Its NAV-001 Antibody-Drug Conjugate Program at the 12th World ADC Conference in London


Nov 30, 2021

Navrogen Announces Publication of Its Block-Removed Immunoglobulin Technology (BRITE) to Optimize Rituximab Activity in Humoral Immunosuppressed Cancers



Sep 13, 2021

Navrogen Enters Into CRADA With USAMRIID To Test Proprietary Small Molecule NK Cell Activators Against SARS-COV-2 Infection


Aug 17, 2021

Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents


Aug 9, 2021

Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders


Feb 4, 2020

Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates (ADCs) to Treat Humoral Immuno-Suppressed Cancers


Jan 31, 2020

Navrogen Opens RandD Operations At Cheyney University



Sep 17, 2019

Navrogen Announces The Closing Of $3.2M Funding To Support Its Humoral Immuno-Oncology Platform Discovery Technologies And Preclinical Pipeline


Google Analytics Alternative